BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang TE, Kao CR, Lin SC, Chang WH, Chu CH, Lin J, Hsieh RK. Salvage therapy for hepatocellular carcinoma with thalidomide. World J Gastroenterol 2004; 10(5): 649-653 [PMID: 14991931 DOI: 10.3748/wjg.v10.i5.649] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Duffy A, Greten T. Developing better treatments in hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2014;4:551-60. [DOI: 10.1586/egh.10.58] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
2 Yau T, Chan P, Wong H, Ng KK, Chok S, Cheung T, Lam V, Epstein RJ, Fan S, Poon RT. Efficacy and Tolerability of Low-Dose Thalidomide as First-Line Systemic Treatment of Patients with Advanced Hepatocellular Carcinoma. Oncology 2007;72:67-71. [DOI: 10.1159/000111709] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
3 Zhu AX. Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be? The Oncologist 2006;11:790-800. [DOI: 10.1634/theoncologist.11-7-790] [Cited by in Crossref: 181] [Cited by in F6Publishing: 172] [Article Influence: 11.3] [Reference Citation Analysis]
4 Chen T, Jia YR, Zhao TJ, Yin ZL. Inhibitory effect of antisense oligonucleotide on the expression of survivin gene and proliferation of human hepatocellular carcinoma cell line SMMC-7721. Shijie Huaren Xiaohua Zazhi 2004; 12(7): 1546-1549 [DOI: 10.11569/wcjd.v12.i7.1546] [Reference Citation Analysis]
5 Sanchez W, Talwalkar JA. Palliative care for patients with end-stage liver disease ineligible for liver transplantation. Gastroenterol Clin North Am 2006;35:201-19. [PMID: 16530121 DOI: 10.1016/j.gtc.2005.12.007] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
6 Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP. A Phase II Study of Epirubicin and Thalidomide in Unresectable or Metastatic Hepatocellular Carcinoma. The Oncologist 2005;10:392-8. [DOI: 10.1634/theoncologist.10-6-392] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
7 Yang W, Wang D, Huang L, Chen Y, Wen S, Hong Q, Kang D. Thalidomide Combined with Transcatheter Arterial Chemoembolization (TACE) for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and GRADE Approach. Asian Pac J Cancer Prev 2018;19:2043-55. [PMID: 30139041 DOI: 10.22034/APJCP.2018.19.8.2043] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Shiah H, Chao Y, Chen L, Yao T, Huang J, Chang J, Chen P, Chuang T, Chin Y, Whang-peng J, Liu T. Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2006;58:654-64. [DOI: 10.1007/s00280-006-0203-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
9 Han CJ. Recent developments in systemic chemotherapy for hepatocellular carcinoma. Korean J Hepatol 2008;14:4. [DOI: 10.3350/kjhep.2008.14.1.4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Ormandy LA, Färber A, Cantz T, Petrykowska S, Wedemeyer H, Hörning M, Lehner F, Manns MP, Korangy F, Greten TF. Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J Gastroenterol 2006; 12(20): 3275-3282 [PMID: 16718852 DOI: 10.3748/wjg.v12.i20.3275] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 58] [Article Influence: 4.1] [Reference Citation Analysis]
11 Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol. 2004;41:864-880. [PMID: 15519663 DOI: 10.1016/j.jhep.2004.09.006] [Cited by in Crossref: 250] [Cited by in F6Publishing: 236] [Article Influence: 14.7] [Reference Citation Analysis]
12 Pinter M, Wichlas M, Schmid K, Plank C, Müller C, Wrba F, Peck-radosavljevic M. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial: . European Journal of Gastroenterology & Hepatology 2008;20:1012-9. [DOI: 10.1097/meg.0b013e3283036740] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
13 Schwartz JD, Llovet JM. Molecular Targeting in Hepatocellular Carcinoma. In: Kaufman HL, Wadler S, Antman K, editors. Molecular Targeting in Oncology. Totowa: Humana Press; 2008. pp. 165-210. [DOI: 10.1007/978-1-59745-337-0_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Chiou HE, Wang TE, Wang YY, Liu HW. Efficacy and safety of thalidomide in patients with hepatocellular carcinoma. World J Gastroenterol 2006; 12(43): 6955-6960 [PMID: 17109516 DOI: 10.3748/wjg.v12.i43.6955] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
15 Paul SC, Lv P, Xiao Y, An P, Liu S, Luo H. Thalidomide in Rat Liver Cirrhosis: Blockade of Tumor Necrosis Factor-α via Inhibition of Degradation of an Inhibitor of Nuclear Factor-κB. Pathobiology 2006;73:82-92. [DOI: 10.1159/000094492] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
16 Chuah B, Lim R, Boyer M, Ong AB, Wong SW, Kong HL, Millward M, Clarke S, Goh BC. Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncol. 2007;46:234-238. [PMID: 17453375 DOI: 10.1080/02841860600702076] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
17 Sleijfer S, Kruit WH, Stoter G. Thalidomide in solid tumours: the resurrection of an old drug. Eur J Cancer 2004;40:2377-82. [PMID: 15519508 DOI: 10.1016/j.ejca.2004.07.023] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
18 Rizell M, Andersson M, Cahlin C, Hafström L, Olausson M, Lindnér P. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol. 2008;13:66-70. [PMID: 18307022 DOI: 10.1007/s10147-007-0733-3] [Cited by in Crossref: 101] [Cited by in F6Publishing: 97] [Article Influence: 7.2] [Reference Citation Analysis]
19 Chen LT, Liu TW, Chao Y, Shiah HS, Chang JY, Juang SH, Chen SC, Chuang TR, Chin YH, Whang-Peng J. alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2005;22:217-226. [PMID: 16091059 DOI: 10.1111/j.1365-2036.2005.02547.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 1.9] [Reference Citation Analysis]
20 Schwartz JD, Sung M, Schwartz M, Lehrer D, Mandeli J, Liebes L, Goldenberg A, Volm M. Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist 2005;10:718-27. [PMID: 16249352 DOI: 10.1634/theoncologist.10-9-718] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
21 Thomas M. Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol 2009;44:136-41. [DOI: 10.1007/s00535-008-2252-z] [Cited by in Crossref: 75] [Cited by in F6Publishing: 65] [Article Influence: 5.8] [Reference Citation Analysis]
22 Chang CW, Wang TE, Chen LT, Chang WH, Leu YS, Fan YK, Chan YJ. Unusual presentation of metastatic hepatocellular carcinoma in the nasal septum: a case report and review of the literature. Med Oncol 2008;25:264-8. [PMID: 18040899 DOI: 10.1007/s12032-007-9028-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
23 Ribatti D, Vacca A, Nico B, Sansonno D, Dammacco F. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. Cancer Treat Rev. 2006;32:437-444. [PMID: 16870349 DOI: 10.1016/j.ctrv.2006.06.002] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 3.4] [Reference Citation Analysis]
24 Patt YZ, Hassan MM, Lozano RD, Nooka AK, Schnirer II, Zeldis JB, Abbruzzese JL, Brown TD. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer. 2005;103:749-755. [PMID: 15660400 DOI: 10.1002/cncr.20821] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 4.4] [Reference Citation Analysis]
25 Lv P, Paul SC, Xiao Y, Liu S, Luo H. Effects of thalidomide on the expression of adhesion molecules in rat liver cirrhosis. Mediators Inflamm 2006;2006:93253. [PMID: 17047296 DOI: 10.1155/MI/2006/93253] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
26 Zacharoulis D, Hatzitheofilou C, Athanasiou E, Zacharoulis S. Antiangiogenic strategies in hepatocellular carcinoma: current status. Expert Review of Anticancer Therapy 2014;5:645-56. [DOI: 10.1586/14737140.5.4.645] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
27 Shao YY, Lin ZZ, Hsu C, Lee KD, Hsiao CH, Lu YS, Huang CC, Shen YC, Hsu CH, Cheng AL. Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. Oncology. 2012;82:59-66. [PMID: 22310088 DOI: 10.1159/000336126] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
28 Ponferrada A, Salcedo M, Matilla A, Núñez O, Bañares R, Álvarez E, Clemente G. Heterogeneidad clínica y evolutiva del hemangioendotelioma epitelioide hepático. Gastroenterología y Hepatología 2005;28:321-5. [DOI: 10.1157/13076348] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
29 Yeh CC, Lin JT, Jeng LB, Ho HJ, Yang HR, Wu MS, Kuo KN, Wu CY. Nonsteroidal anti-inflammatory drugs are associated with reduced risk of early hepatocellular carcinoma recurrence after curative liver resection: a nationwide cohort study. Ann Surg 2015;261:521-6. [PMID: 24950265 DOI: 10.1097/SLA.0000000000000746] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
30 Chen YY, Yen HH, Chou KC, Wu SS. Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: A retrospective analysis. World J Gastroenterol 2012; 18(5): 466-471 [PMID: 22346253 DOI: 10.3748/wjg.v18.i5.466] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
31 Han SH, Park SH, Kim JH, Lee JJ, Kwon SY, Kwon OS, Kim SS, Kim JH, Kim KK, Park YH, Lee JN, Nam E, Bang SM, Cho EK, Shin DB, Lee JH. Thalidomide for treating metastatic hepatocellular carcinoma: a pilot study. Korean J Intern Med 2006;21:225-9. [PMID: 17249503 DOI: 10.3904/kjim.2006.21.4.225] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
32 Chen S, Tsai H, Jan C, Wang Y, Chen L. Low dose of thalidomide can be effective in advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2006;21:1868-9. [DOI: 10.1111/j.1440-1746.2006.04303.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]